Opendata, web and dolomites

AltCheM SIGNED

In vivo functional screens to decipher mechanisms of stochastically- and mutationally-induced chemoresistance in Acute Myeloid Leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AltCheM project word cloud

Explore the words cloud of the AltCheM project. It provides you a very rough idea of what is the project "AltCheM" about.

pooled    examined    mutationally    chip    shrna    modes    myeloid    ultimately    screen    acute    mll    patients    consecutive    model    expansion    genetically    rounds    collection    innovative    mutational    chemotherapy    stochastic    resistance    af9    combining    initiating    remission    almost    decades    disease    sustained    screening    agents    mechanisms    effectors    profiling    leukemia    decipher    survive    standard    hematology    chemoresistance    genesis    consequence    rna    diagnosed    intrinsically    aml    residual    actively    front    mutations    molecular    exome    underlying    persistence    emergence    regardless    chemoresistant    biological    virtue    experiments    reading    mrd    resist    resistant    chemotherapeutic    relevance    despite    relapse    vivo    therapies    frame    tested    minimal    initial    pursue    status    mutant    libraries    combinations    autonomous    cells    poorly    few    predetermined    conduct    firmly    re    sequencing    characterization    adults    predict    paradigm    fraction    genomic    treatment    fundamental    cell    stochastically    mice    functional    mouse    line    prone    chemoprotective    therapy   

Project "AltCheM" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2023-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙500˙000.00

Map

 Project objective

Acute Myeloid Leukemia (AML), the most common leukemia diagnosed in adults, represents the paradigm of resistance to front-line therapies in hematology. Indeed, AML is so genetically complex that only few targeted therapies are currently tested in this disease and chemotherapy remains the only standard treatment for AML since the past four decades. Despite an initial sustained remission achieved by chemotherapeutic agents, almost all patients relapse with a chemoresistant minimal residual disease (MRD). The goal of my proposal is to characterize the still poorly understood biological mechanisms underlying persistence and emergence of MRD. MRD is the consequence of the re-expansion of leukemia-initiating cells that are intrinsically more resistant to chemotherapy. This cell fraction may be stochastically more prone to survive front-line therapy regardless of their mutational status (the stochastic model), or genetically predetermined to resist by virtue of a collection of chemoprotective mutations (the mutational model). I have already generated in mice, by consecutive rounds of chemotherapy, a stochastic MLL-AF9-driven chemoresistance model that I examined by RNA-sequencing. I will pursue the comprehensive cell autonomous and cell non-autonomous characterization of this chemoresistant AML disease using whole-exome and ChIP-sequencing. To establish a mutationally-induced chemoresistant mouse model, I will conduct an innovative in vivo screen using pooled mutant open reading frame and shRNA libraries in order to predict which combinations of mutations, among those already known in AML, actively promote chemoresistance. Finally, by combining genomic profiling and in vivo shRNA screening experiments, I will decipher the molecular mechanisms and identify the functional effectors of these two modes of resistance. Ultimately, I will then be able to firmly establish the fundamental relevance of the stochastic and/or the mutational model of chemoresistance for MRD genesis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALTCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALTCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

MITOvTOXO (2020)

Understanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell

Read More